VSV-Pseudovirus_SARS-CoV-2 Delta Luciferase, ReVacc Scientific

Supplier: ReVacc Scientific

D33Z75-200UL D33Z75-1ML
76519-250EA 1017.08 CAD
76519-250 76519-252
VSV-Pseudovirus_SARS-CoV-2 Delta Luciferase, ReVacc Scientific
Vectors, Plasmids and Libraries

This pseudotyped virus uses recombinant vesicular stomatitis virus (rVSV) to carry the S protein of SARS-CoV-2 (GenBank: MN908947) with multiple mutations initially identified in variant of B.1.617.2 (Delta strain), and 18-aa cytoplasmic tail truncation for optimal infection.


Infection of cells with this pseudotyped virus carrying luciferase reporter results in high level luciferase activity. See our titration result showing the undiluted pseudovirus generates signal over 10000-fold higher than uninfected control (cell alone as background). The neutralizing activity of control mAbs was tested by using this pseudotyped virus.


As pseudovirus infectivity of rVSV without its original G is restricted to a single round of replication, the pseudotypes can be handled using BSL-2 containment practices. Applications:
•Anti-SARS-CoV-2 neutralizing antibody screening at high throughput
•Anti-SARS-CoV-2 drug screening at high throughput
•SARS-CoV-2 pseudovirus transduction of target cells for viral entry and functional studies


See suggested protocol to use this product.


Packaging: Shipping with dry ice. Require –80 °C storage. Multiple freeze/thaw cycles will reduce its sensitivity. Recommend only 1 cycle. Aliquot after the first thaw.


Caution: Handle it in biosafety cabinet in BSL-2. Contacted tips and tubes should be decontaminated by 10% disinfecting bleach. For research use only.

Order Now


Learn more

About VWR

Avantor is a vertically integrated, global supplier of discovery-to-delivery solutions for...

Learn more About VWR